Tool hope to release a new album and put on a residency at Las Vegas’ Sphere in 2027

Tool expects to release a new album and pursue a residency at Las Vegas’s Sphere in 2027, with drummer Danny Carey saying the band is “working on a lot of new Tool songs” and has been in discussions with the venue. The plan highlights the commercial opportunity of immersive multimedia residencies (the Sphere has drawn interest from major acts such as Metallica) and suggests a potentially resource‑intensive leadup with initial shows described as “a few shows before you make any money,” while band members continue other projects and festival commitments.

Analysis

Market structure: Major beneficiaries are the Sphere operator (MSGE), large promoters/ticketing platforms (Live Nation, LYV), and Las Vegas resort operators (MGM, MGM; Caesars, CZR) via higher room rates, F&B and premium ticketing revenue; experiential-AV vendors and premium hospitality segments also gain pricing power as residencies shift supply from one-off tours to concentrated venue runs. Smaller clubs, secondary festivals and some regional promoters could lose share as established acts prioritize high-margin residencies; expect premium ticket pricing power to lift per-capita spend by an estimated 10–30% for headline residencies.

Risk assessment: Tail risks include technical/production failure at immersive venues, artist scheduling delays, regulatory action on dynamic pricing/scalping, or tourism shocks (air travel disruptions) that could wipe out expected incremental cash flows; probability low but impact high (10–30% revenue swing). Immediate moves (days–weeks) will be sentiment-driven around announcements; short-term (3–12 months) depends on presale strength; long-term (12–36 months) depends on confirmed residency contracts and album release timing.

Trade implications: Tactical trades favor owners/promoters with durable cashflow: establish modest long exposure to MSGE (Sphere owner) and LYV ahead of formal residency deals, use 12–24 month call structures to capture 2027 upside while capping cost. Hedge with short/underweight small-cap venue integrators or regional casino operators; options strategies (buying LEAP calls funded by selling nearer-term OTM calls) exploit expected asymmetric upside around announcement and album release.

Contrarian view: The market likely underestimates cannibalization and CAPEX strain — residencies concentrate revenue but increase fixed-cost commitments and tech amortization, pressuring margins if attendance or pricing disappoints. The initial stock pop on announcement can be overdone (>15%); historically Vegas residencies give durable but front-loaded hotel upside, not indefinite growth, so fade headline-driven rallies and preferentially buy post-confirmation weakness.

Key Decisions for Investors

• Establish a 1.5–2.5% portfolio long in Madison Square Garden Entertainment (MSGE) using 12–24 month call spreads (buy LEAP ~ATM, sell ~+20% OTM) to capture Sphere-driven revenue into 2027; trim or take profits if position rallies >25% or if presales disappoint within 90 days of residency announcement.
• Initiate 1–2% combined long exposure to MGM Resorts (MGM) and Caesars (CZR), 50/50 weight, to capture incremental room/ancillary spend from high-profile residencies; use Feb 2028 LEAP calls or buy stock with a 15% stop-loss and target 20–35% upside by Q4 2027 contingent on sustained tourism metrics.
• Buy 1% notional of Live Nation (LYV) 12–18 month LEAP calls ~20% OTM funded by selling 1–3 month OTM calls to monetize carry; add to position on confirmed residency/album release and if ticket presales exceed 70% within first 72 hours.
• Short or avoid small-cap experiential AV/venue integrators with >30% revenue concentration in single projects (identify candidates with revenue drops >20% post-contract); size at 0.5–1% and cover if counterparty announces multi-year recurring contracts or government subsidies within 6 months.